Halozyme Therapeutics (NASDAQ:HALO) Trading Down 8.7% on Disappointing Earnings

Halozyme Therapeutics, Inc. (NASDAQ:HALO)’s stock price dropped 8.7% during trading on Wednesday following a weaker than expected earnings announcement. The company traded as low as $73.00 and last traded at $73.4740. Approximately 2,311,550 shares were traded during mid-day trading, an increase of 17% from the average daily volume of 1,975,592 shares. The stock had previously closed at $80.48.

The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the consensus estimate of $1.92 by ($2.16). The business had revenue of $451.77 million for the quarter, compared to analyst estimates of $446.13 million. Halozyme Therapeutics had a return on equity of 105.87% and a net margin of 22.69%.The business’s revenue for the quarter was up 51.6% compared to the same quarter last year. During the same quarter last year, the company earned $1.26 EPS.

Key Stories Impacting Halozyme Therapeutics

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Halozyme reported record full‑year 2025 total revenue of $1.397 billion and reiterated strong 2026 guidance including total revenue of $1.71–$1.81B, adjusted EBITDA of $1.125–$1.205B and non‑GAAP EPS of $7.75–$8.25 — a clear signal of expected profitability surge next year. Halozyme Reports Full Year 2025 Record Revenue
• Positive Sentiment: Royalty revenue was a key growth engine — royalties rose ~52% year‑over‑year to a record level, underpinning the top‑line strength and recurring cash generation. Zacks: Higher Royalties Drive Revenues
• Positive Sentiment: Management completed strategic acquisitions (Elektrofi’s Hypercon and Surf Bio’s Hyperconcentration tech) that could expand product/tech optionality and long‑term upside. Acquisitions Mentioned in PR
• Neutral Sentiment: Analyst coverage is mixed but generally constructive: several buy ratings and a median 6‑ to 12‑month target above current price suggest upside, though targets vary widely — valuation and expectations matter going forward. Yahoo: Valuation Signals
• Negative Sentiment: Q4 surprised the street with a loss (EPS swung negative) largely due to an acquisition charge and related one‑time items; EPS missed consensus badly despite revenue slightly topping estimates — that unexpected swing pressured the stock. MarketWatch: Stock Declines on Surprise 4Q Loss
• Negative Sentiment: Balance‑sheet and operating items drew attention: operating loss widened in Q4, liabilities increased year‑over‑year, and heavy insider selling was flagged by some data providers — factors that can amplify near‑term downside. QuiverQuant: Q4 Financials & Insider Activity

Analyst Upgrades and Downgrades

Several equities analysts have commented on HALO shares. The Goldman Sachs Group reiterated a “sell” rating and set a $56.00 price target on shares of Halozyme Therapeutics in a report on Thursday, December 4th. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 31st. Weiss Ratings upgraded shares of Halozyme Therapeutics from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, February 10th. Benchmark restated a “buy” rating on shares of Halozyme Therapeutics in a report on Tuesday, February 3rd. Finally, JPMorgan Chase & Co. raised their price target on Halozyme Therapeutics from $63.00 to $65.00 and gave the company a “neutral” rating in a research report on Monday, October 27th. Seven investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Halozyme Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $77.44.

Insider Activity

In related news, CEO Helen Torley sold 20,000 shares of the stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $76.12, for a total value of $1,522,400.00. Following the completion of the sale, the chief executive officer owned 708,719 shares in the company, valued at approximately $53,947,690.28. This trade represents a 2.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Bernadette Connaughton sold 2,000 shares of the business’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $70.25, for a total value of $140,500.00. Following the transaction, the director owned 40,123 shares in the company, valued at $2,818,640.75. This represents a 4.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 49,398 shares of company stock worth $3,650,592. Insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Root Financial Partners LLC bought a new position in shares of Halozyme Therapeutics during the 3rd quarter worth about $25,000. Measured Wealth Private Client Group LLC lifted its stake in Halozyme Therapeutics by 51.5% during the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 124 shares during the period. Larson Financial Group LLC boosted its holdings in Halozyme Therapeutics by 3,118.2% during the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 343 shares in the last quarter. Richardson Financial Services Inc. grew its stake in shares of Halozyme Therapeutics by 87.6% in the 3rd quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 198 shares during the period. Finally, Newbridge Financial Services Group Inc. acquired a new position in shares of Halozyme Therapeutics in the 2nd quarter worth approximately $32,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Price Performance

The company has a 50-day moving average of $71.77 and a 200 day moving average of $70.27. The company has a debt-to-equity ratio of 1.59, a quick ratio of 1.37 and a current ratio of 1.59. The firm has a market cap of $8.61 billion, a P/E ratio of 29.41, a P/E/G ratio of 0.33 and a beta of 0.97.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.